Clinical potential of photodynamic therapy in cardiovascular disorders

American Journal of Cardiovascular Drugs

Volumn 1, Issue 1, 2001, Pages 15-21

  Kossodo, Sylvie ^a   LaMuraglia, Glenn M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOTOSENSITIZING AGENT;

ANIMAL; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERPLASIA; INTIMA; PATHOLOGY; PHOTOCHEMOTHERAPY; RADIATION EXPOSURE; RESTENOSIS; REVIEW;

ANIMALS; CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; CORONARY RESTENOSIS; HUMANS; HYPERPLASIA; MYOCARDIAL REVASCULARIZATION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; TUNICA INTIMA;

EID: 1842531894     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/00129784-200101010-00002     Document Type: Review

References (79)

1. Centers for Disease Control and Prevention. National Center for Chronic Disease Prevention and Health Promotion. Cardiovascular diseases. Available from: URL: http://www.cdc.gov/nccdphp/cardiov.htm [Accessed 2000 Nov 14]
2. Schwartz RS, Topol EJ, Serruys PW, et al. Artery size, neointima, and remodeling: time for some standards. J Am Coll Cardiol 1998 Dec; 32 (7): 2087-94
3. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloonexpandable- stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994 Aug 25; 331 (8): 489-95
4. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994 Apr 9; 343 (8902): 881-6
5. Maresta A, Balducelli M, Cantini L, et al. Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty: results of the randomized, doubleblind STARC study Studio Trapidil versus Aspirin nella Restenosi Coronarica. Circulation 1994 Dec; 90 (6): 2710-5
6. Cote G, Tardif JC, Lesperance J, et al., Multivitamins and Protocol Study Group. Effects of probucol on vascular remodeling after coronary angioplasty. Circulation 1999 Jan 5-12;99 (1): 30-5
7. Raizner AE, Oesterle SN, Waksman R, et al. Inhibition of restenosis with beta-emitting radiotherapy: report of the Proliferation Reduction with Vascular Energy Trial (PREVENT). Circulation 2000 Aug 29; 102 (9): 951-8
8. Tamai H, Katoh O, Suzuki S, et al. Impact of tranilast on restenosis after coronary angioplasty: tranilast restenosis following angioplasty trial (TREAT). Am Heart J 1999 Nov; 138 (5 Pt 1): 968-75
9. Smith RC, Walsh K. Gene therapy for restenosis. Curr Cardiol Rep 2000 Jan; 2 (1): 13-23
10. Teirstein PS, Massullo V, Jani S, et al. Two-year follow-up after catheter-based radiotherapy to inhibit coronary restenosis. Circulation 1999 Jan 19; 99 (2): 243-7
11. Ortu P, LaMuraglia GM, Roberts GW, et al. Photodynamic therapy of arteries: a novel approach for treatment of experimental intimal hyperplasia. Circulation 1992 Mar; 85 (3): 1189-96
12. Rockson SG, Lorenz DP, Cheong WF, et al. Photoangioplasty: an emerging clinical cardiovascular role for photodynamic therapy. Circulation 2000 Aug 1; 102 (5): 591-6
13. Rockson SG, Kramer P, Razavi M, et al. Photoangioplasty for human peripheral atherosclerosis: results of a phase I trial of photodynamic therapy with motexafin lutetium. Circulation 2000 Nov 7; 102 (19): 2322-4
14. Hendersen BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol 1992 Jan; 55 (1): 145-57
15. Ochsner M. Photophysical and photobiological processes in the photodynamic therapy of tumours. J Photochem Photobiol B. 1997 May; 39 (1): 1-18
16. Moan J, Peng Q, Sorensen R, et al. The biophysical foundations of photodynamic therapy. Endoscopy 1998 May; 30 (4): 387-91
17. Freeman BA, Crapo JD. Biology of disease: free radicals and tissue injury. Lab Invest 1982 Nov; 47 (5): 412-26
18. Spears JR, Serur J, Shropshire D, et al. Fluorescence of experimental atheromatous plaques with hematoporphyrin derivative. J Clin Invest 1983 Feb; 71 (2): 395-9
19. Neave V, Giannotta S, Hyman S, et al. Hematoporphyrin uptake in atherosclerotic plaques: therapeutic potentials. Neurosurgery 1988 Sep; 23 (3): 307-12
20. Vever-Bizet C, L'Epine Y, Delettre E, et al. Photofrin II uptake by atheroma in atherosclerotic rabbits: fluorescence and high performance liquid chromatographic analysis on post-mortem aorta. Photochem Photobiol 1989 Jun; 49 (6): 731-7
21. Litvack F, Grundfest WS, Forrester JS, et al. Effects of hematoporphyrin derivative and photodynamic therapy on atherosclerotic rabbits. Am J Cardiol 1985 Oct 1; 56 (10): 667-71
22. Eton D, Colburn MD, Shim V, et al. Inhibition of intimal hyperplasia by photodynamic therapy using photofrin. J Surg Res 1992 Dec; 53 (6): 558-62
23. Hsiang YN, Crespo MT, Machan LS, et al. Photodynamic therapy for atherosclerotic stenoses in Yucatan miniswine. Can J Surg 1994 Apr; 37 (2): 148-52
24. Feyh J, Kastenbauer E. Treatment of laryngeal papillomatosis with photodynamic laser therapy. Laryngorhinootologie 1992 Apr; 71 (4): 190-2
25. Dougherty TJ, Cooper MT, Mang TS. Cutaneous phototoxic occurrences in patients receiving Photofrin. Lasers Surg Med 1990; 10 (5): 485-8
26. Kavuru MS, Mekta AC.Treatment of recurrent respiratory papillomatosis. N Engl J Med 1992 Jan 16; 326 (3): 204-5
27. Wenig BL, Kurtzmann DM. Photodynamic therapy in the treatment of squamous cell carcinomas of the head and neck. Arch Otolaryngol Head Neck Surg 1990 Nov; 116 (11): 1267-70
28. Ofner JG, Schlogl H, Kostron H. Unusual adverse reaction in a patient sensitized with Photosan 3. J Photochem Photobiol B 1996 Nov; 36 (2): 183-4
29. Levy JG. Photosensitizers in photodynamic therapy. Semin Oncol 1994 Dec; 21 (6 Suppl. 15): 4-10
30. LaMuraglia GM, Ortu P, Flotte TJ, et al. Chloaluminum sulfonated phtalocyanine partitioning in normal and intimal hyperplastic artery in the rat: implications for photodynamic therapy. Am J Pathol 1993 Jun; 142 (6): 1898-905
31. Orth K, Ruck A, Beck G, et al. Photodynamic therapy of small adenocarcinomas with methylene blue. Chirurg 1995 Dec; 66 (12): 1254-7
32. Heckenkamp J, Adili F, Kishimoto J, et al. Local photodynamic action of methylene blue favorably modulates the postinterventional vascular wound healing response. J Vasc Surg 2000 Jun; 31 (6): 1168-77
33. Hsiang YN, Crespo MT, Richter AM, et al. In vitro and in vivo uptake of benzoporphyrin derivative into human and miniswine atherosclerotic plaque. Photochem Photobiol 1993 Apr; 57 (4): 670-4
34. Adili F, Statius van Eps RG, Flotte TJ, et al. Photodynamic therapy with local photosensitizer delivery inhibits experimental intimal hyperplasia. Lasers Surg Med 1998; 23 (5): 263-73
35. Nyamekye I, Anglin S, McEwan J, et al. Photodynamic therapy of normal and balloon-injured rat carotid arteries using 5-amino-levulinic acid. Circulation 1995 Jan 15; 91 (2): 417-25
36. Jenkins MP, Buonaccorsi G, MacRobert A, et al. Intra-arterial photodynamic therapy using 5-ALA in a swine model. Eur J Vasc Endovasc Surg 1998 Oct; 16 (4): 284-91
37. Jenkins MP, Buonaccorsi GA, Raphael M, et al. Clinical study of adjuvant photodynamic therapy to reduce restenosis following femoral angioplasty. Br J Surg 1999 Oct; 86 (10): 1258-63
38. Herman MA, Webber J, Fromm D, et al. Hemodynamic effects of 5-aminolevulinic acid in humans. Photochem Photobiol B 1998 Apr; 43 (1): 61-5
39. Sessler JL, Murai T, Lynch V, et al. An expanded porphyrin: the synthesis and structure of a new aromatic pentadentate ligand. J Am Chem Soc 1988, 110: 5586-8
40. Woodburn KW, Fan Q, Kessel D, et al. Phototherapy of cancer and atheromatous plaque with texaphyrins. J Clin Laser Med Surg 1996 Oct; 14 (5): 343-8
41. Sessler JL, Miller RA. Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem Pharmacol 2000 Apr 1; 59 (7): 733-9
42. Wolinsky H. Historical perspective. Semin Interv Cardiol 1996 Mar; 1 (1): 3-7
43. Gonschior P, Erdemci A, Gerheuser F, et al. Selective hematoporphyrin derivative (HMD) application in arterial vessels using a porous balloon catheter results in equivalent levels as compared to high-dose systemic administration. Z Kardiol 1991 Dec; 80 (12): 738-45
44. Gonschior P, Vogel-Wiens C, Goetz AE, et al. Endovascular catheter-delivered photodynamic therapy in an experimental response to injury model. Basic Res Cardiol 1997 Oct; 92 (5): 310-9
45. Dick A, Kromen W, Jungling E, et al. Quantification of horseradish peroxidase delivery into the arterial wall in vivo as a model of local drug treatment: comparison between a porous and a gel-coated balloon catheter. Cardiovasc Intervent Radiol 1999 Sep-Oct; 22 (5): 389-93
46. Fisher AMR, Muphree AL, Gomer CS. Clinical and preclinical photodynamic therapy. Laser Surg Med 1995; 17 (1): 2-31
47. Wieman TJ. Lasers and the surgeon. Am J Surg 1986 Apr; 151 (4): 493-500
48. Dwyer PJ, White WM, Fabian RL, et al. Optical integrating balloon device for photodynamic therapy. Lasers Surg Med 2000; 26 (1): 58-66
49. Van den Bergh H. On the evolution of some endoscopic light delivery systems for photodynamic therapy. Endoscopy 1998 May; 30 (4): 392-407
50. Morcos NC, Berns M, Henry WL. Phycocyanin: laser activation, cytotoxic effects, and uptake in human atherosclerotic plaque. Lasers Surg Med 1988; 8 (1): 10-7
51. Visona A, Jori G. Targeting of experimentally induced atherosclerotic lesions by liposome-delivered Zn(II)-phthalocyanine. Atherosclerosis 1993 May; 100 (2): 213-22
52. Hsiang YN, Todd ME, Bower RD. Determining light dose for photodynamic therapy of atherosclerotic lesions in the Yucatan miniswine. J Endovasc Surg 1995 Nov; 2 (4): 365-71
53. Katoh T, Asahara T, Naitoh Y, et al. In vivo intravascular laser photodynamic therapy in rabbit atherosclerotic lesions using a lateral direction fiber. Lasers Surg Med 1997; 20 (4): 373-81
54. Woodburn KW. Atheromatous plaque reduction with AntrinTMphotoangioplasty [abstract]. Lasers Surg Med 1999; Suppl. 11: 53 [abstract no. 228]
55. Hayashi J, Saito T, Aizawa K. Change in chemical composition of lipids accumulated in atheromas of rabbits following photodynamic therapy. Lasers Surg Med 1997; 21 (3): 287-93
56. Pharmacyclics. Clinical research program. Antrin® Photosensitizer Phase II Trial for Peripheral Arterial Disease. Available at: URL: http:// www. pcyc.com/Website/HomePage/homepage.htm [Accessed 2000 Nov 16]
57. Pharmacyclics. Clinical research program. Antrin® Photosensitizer Phase I Trial For Coronary Artery Disease. Available at: URL: http:// www. pcyc.com/Website/HomePage/homepage.htm [Accessed 2000 Nov 16]
58. Nyamekye I, Buonaccorsi G, McEwan J, et al. Inhibition of intimal hyperplasia in balloon injured arteries with adjunctive phthalocyanine sensitised photodynamic therapy. Eur J Vasc Endovasc Surg 1996 Jan; 11 (1): 19-28
59. LaMuraglia GM, ChandraSekar NR, Flotte TJ, et al. Photodynamic therapy inhibition of experimental intimal hyperplasia: acute and chronic effects. J Vasc Surg 1994 Feb; 19 (2): 321-9;[discussion 329-31]
60. Grant WE, Buonaccorsi G, Speight PM, et al. The effect of photodynamic therapy on the mechanical integrity of normal rabbit carotid arteries. Laryngoscope 1995 Aug; 105 (8 Pt 1): 867-71
61. LaMuraglia GM, Schiereck J, Heckenkamp J, et al. Photodynamic therapy induces apoptosis in intimal hyperplastic arteries. Am J Pathol 2000 Sep; 157 (3): 867-75
62. Statius van Eps RG, LaMuraglia GM. Photodynamic therapy inhibits transforming growth factor a activity associated with vascular smooth muscle cell injury. J Vasc Surg 1997 Jun; 25 (6): 1044-52;[discussion 1052-3]
63. Statius van Eps RG, Adili F, Watkins MT, et al. Photodynamic therapy of extracellular matrix stimulates endothelial cell growth by inactivation of matrix-associated transforming growth factor-a. Lab Invest 1997 Feb; 76 (2): 257-66
64. LaMuraglia GM, Adili F, Karp SJ, et al. Photodynamic therapy inactivates extracellular matrix-basic fibroblast growth factor: insights to its effect on the vascular wall. J Vasc Surg 1997 Aug; 26 (2): 294-301
65. Statius van Eps RG, Adili F, LaMuraglia GM. Photodynamic therapy inactivates cell-associated basic fibroblast growth factor: a silent way of vascular smooth muscle cell eradication. Cardiovasc Res 1997 Aug; 35 (2): 334-40
66. Overhaus M, Heckenkamp J, Kossodo S, et al. Photodynamic therapy generates a matrix barrier to invasive vascular cell migration. Circ Res 2000 Feb 18; 86 (3): 334-40
67. Statius van Eps RG, ChandraSekar NR, Hasan T, et al. Importance of the treatment field for the application of vascular photodynamic therapy to inhibit intimal hyperplasia. Photochem Photobiol 1998 Mar; 67 (3): 337-42
68. Mollnes TE, Fiane AE. Xenotransplantation: how to overcome the complement obstacle? Mol Immunol 1999 Mar-Apr; 36 (4-5):269-76
69. Hayry P. Chronic allograft vasculopathy: new strategies for drug development. Transplant Proc 1998 Dec; 30 (8): 3989-90
70. LaMuraglia GM, Adili F, Schmitz-Rixen T, et al. Photodynamic therapy inhibits experimental allograft rejection: a novel approach for the development of vascular bioprostheses. Circulation 1995 Oct 1; 92 (7): 1919-26
71. Dougherty TJ. Photodynamic therapy (PDT) of malignant tumors. Crit Rev Oncol Hematol 1984; 2 (2): 83-116
72. McCaughan Jr JS. Photodynamic therapy: a review. Drugs Aging 1999 Jul; 15 (1): 49-68
73. Villeneuve L. Ex vivo photodynamic purging in chronic myelogenous leukaemia and other neoplasias with rhodamine derivatives. Biotechnol Appl Biochem 1999 Aug; 30 (Pt 1): 1-17
74. Jin ML, Yang BQ, Zhang W, et al. Combined treatment with photodynamic therapy and chemotherapy for advanced cardiac cancers J Photochem Photobiol B 1992 Jan; 12 (1): 101-6
75. Adili F, Statius van Eps RG, LaMuraglia GM. Significance of dosimetry in photodynamic therapy of injured arteries: classification of biological responses. Photochem Photobiol 1999 Oct; 70 (4): 663-8
76. Lin GC, Tsoukas ML, Lee MS, et al. Skin necrosis due to photodynamic action of benzoporphyrin depends on circulating rather than tissue drug levels: implications for control of photodynamic therapy. Photochem Photobiol 1998 Oct; 68 (4): 575-83
77. Eton D, Borhani M, Spero K, et al. Photodynamic therapy: cytotoxicity of aluminum phthalocyanine on intimal hyperplasia. Arch Surg 1995 Oct; 130 (10): 1098-103
78. Luo Y, Kessel D. Initiation of apoptosis versus necrosis by photodynamic therapy with chloroaluminum phthalocyanine. Photochem Photobiol 1997 Oct; 66 (4): 479-83
79. Star WM. Light dosimetry in vivo. Phys Med Biol 1997 May; 42 (5): 763-87